Cetilistat_product_DataBase

Bioactivity

Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively[1].

Target

IC50: 54.8 nM (rat pancreatic lipase), 5.95 nM (human pancreatic lipase)

Invitro

Cetilistat inhibits rat pancreatic lipase activity with an IC50 of 54.8 nM. Also, Cetilistat inhibits human pancreatic lipase activity with an IC50 of 5.95 nM, which is 9.2 times more potent than for rat pancreatic lipase[1].

In Vivo

Cetilistat (3, 10, 30, or 100 mg/kg) reduces intestinal fat absorption by inhibiting pancreatic lipase activity in male SD rats[1].Cetilistat (4.9, 14.9, or 50.7 mg/kg; mixed into powdered high-fat diet; once a day; for three weeks) shows anti-obesity and antihyperlipidemic effects on DIO F344 rats by reducing intestinal fat absorption[1]. Animal Model:

Name

Cetilistat

CAS

282526-98-1

Formula

C25H39NO3

Molar Mass

401.58

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Yamada Y, et al. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res. 2008 Aug;40(8):539-43.

PeptideDB

Cetilistat

CAS: 282526-98-1 F: C25H39NO3 W: 401.58